A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”). We also produce pods for Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. Market Opportunity: Management of Diabetes Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.7B | 2.7B | 2.1B | 1.7B | 1.3B | 1.1B |
| Net Income | 247M | 247M | 418M | 206M | 4.6M | 17M |
| EPS | $3.48 | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 |
| Free Cash Flow | 378M | 378M | 305M | 70M | -3.9M | -180M |
| ROIC | 19.5% | 19.8% | 17.9% | 14.2% | 1.8% | 9.7% |
| Gross Margin | 71.6% | 71.6% | 69.8% | 68.3% | 61.7% | 69.7% |
| Debt/Equity | 0.64 | 0.64 | 1.21 | 2.00 | 3.00 | 2.34 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 474M | 474M | 309M | 220M | 38M | 126M |
| Operating Margin | 17.5% | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% |
| ROE | 16.3% | 18.1% | 34.5% | 28.2% | 1.0% | 3.0% |
| Shares Outstanding | 71M | 71M | 72M | 70M | 66M | 70M |
INSULET CORP passes 6 of 9 quality checks, suggesting mixed fundamentals.
INSULET CORP trades at 56.8x trailing earnings, compared to its 15-year median P/E of 74.6x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 36.9x vs a median of 58.6x. The company's 5-year average ROIC is 12.7% with a gross margin of 68.2%. Total shareholder yield (buybacks) is 0.4%. At current prices, the estimated annualized return to fair value is +141.1%.
INSULET CORP (PODD) has a current P/E ratio of 56.8, compared to its historical median P/E of 74.6. The stock is currently considered Cheap based on its historical valuation range.
INSULET CORP (PODD) has a 5-year average return on invested capital (ROIC) of 12.7%. This indicates solid capital allocation.
INSULET CORP (PODD) has a market capitalization of $14.0B. It is classified as a large-cap stock.
INSULET CORP (PODD) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.42%.
Based on historical P/E analysis, INSULET CORP (PODD) appears cheap. The current P/E of 56.8 is 24% below its historical median of 74.6. The estimated fair value CAGR (P/E method) is 92.1%.
INSULET CORP (PODD) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
INSULET CORP (PODD) reported annual revenue of $2.7 billion in its most recent fiscal year, based on SEC EDGAR filings.
INSULET CORP (PODD) has a net profit margin of 9.1%. This is a modest margin.
INSULET CORP (PODD) generated $378 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
INSULET CORP (PODD) has a debt-to-equity ratio of 0.64. This indicates moderate leverage.
INSULET CORP (PODD) reported earnings per share (EPS) of $3.48 in its most recent fiscal year.
INSULET CORP (PODD) has a return on equity (ROE) of 18.1%. This indicates the company generates strong returns for shareholders.
INSULET CORP (PODD) has a 5-year average gross margin of 68.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for INSULET CORP (PODD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INSULET CORP (PODD) has a book value per share of $21.34, based on its most recent annual SEC filing.